Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria T Bourlon

Showing results (31-40 of 74) with videos related to

Pageof 8
Sort By:
Scientific Reports|March 19, 2022
Muscle wasting assessment tools for prostate cancerAlan Espinosa-Marrón, Aquiles Rubio-Blancas, Christian Aníbal Quiñones-Capistran, et al.
Plant Foods for Human Nutrition (Dordrecht, Netherlands)|July 10, 2026
Preserving Tradition, Preventing Cancer: A Narrative Review of the Traditional Mexican Diet as a Framework for Cancer Risk ReductionIsaura Del Valle-Domínguez, Eduardo Rios-Garcia, Cittim B Palomares-Palomares, et al.
Clinical Genitourinary Cancer|January 16, 2024
Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert OpinionAndrey Soares, Maria T Bourlon, Alvin Wong, et al.
JCO Global Oncology|January 2, 2025
Treatment Patterns for Metastatic Urothelial Carcinoma Across Eight Mexican Centers: The ALEBRIJE StudyEvelyn Lilian Beas-Lozano, Yuly A Remolina-Bonilla, Rosa Caballero, et al.
The Lancet. Oncology|June 10, 2022
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialRobert J Motzer, Thomas Powles, Mauricio Burotto, et al.
JCO Global Oncology|March 26, 2026
Exercise Counseling and Referral Practices Among Oncology Care Physicians in Latin America: A Multinational Survey StudyPaulo Gustavo Bergerot, Cristiane Decat Bergerot, Errol J Philip, et al.
Expert Opinion on Pharmacotherapy|February 4, 2026
Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working groupConcetta Calabrò, Francesco Ciccimarra, Alessandro Rizzo, et al.
Urologic Oncology|May 15, 2026
Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective studyPatricia Rioja, Carolina Passarella, Martín Angel, et al.
Lancet (London, England)|September 16, 2024
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 StudyToni K Choueiri, Laurence Albiges, Philippe Barthélémy, et al.
European Urology Oncology|June 4, 2026
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 StudyPhilipp Cornelius Mandel, Mike Wenzel, María Natalia Gandur Quiroga, et al.
Pageof 8

Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
Scientific Reports|March 19, 2022
Muscle wasting assessment tools for prostate cancerAlan Espinosa-Marrón, Aquiles Rubio-Blancas, Christian Aníbal Quiñones-Capistran, et al.
Plant Foods for Human Nutrition (Dordrecht, Netherlands)|July 10, 2026
Preserving Tradition, Preventing Cancer: A Narrative Review of the Traditional Mexican Diet as a Framework for Cancer Risk ReductionIsaura Del Valle-Domínguez, Eduardo Rios-Garcia, Cittim B Palomares-Palomares, et al.
Clinical Genitourinary Cancer|January 16, 2024
Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert OpinionAndrey Soares, Maria T Bourlon, Alvin Wong, et al.
JCO Global Oncology|January 2, 2025
Treatment Patterns for Metastatic Urothelial Carcinoma Across Eight Mexican Centers: The ALEBRIJE StudyEvelyn Lilian Beas-Lozano, Yuly A Remolina-Bonilla, Rosa Caballero, et al.
The Lancet. Oncology|June 10, 2022
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialRobert J Motzer, Thomas Powles, Mauricio Burotto, et al.
JCO Global Oncology|March 26, 2026
Exercise Counseling and Referral Practices Among Oncology Care Physicians in Latin America: A Multinational Survey StudyPaulo Gustavo Bergerot, Cristiane Decat Bergerot, Errol J Philip, et al.
Expert Opinion on Pharmacotherapy|February 4, 2026
Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working groupConcetta Calabrò, Francesco Ciccimarra, Alessandro Rizzo, et al.
Urologic Oncology|May 15, 2026
Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective studyPatricia Rioja, Carolina Passarella, Martín Angel, et al.
Lancet (London, England)|September 16, 2024
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 StudyToni K Choueiri, Laurence Albiges, Philippe Barthélémy, et al.
European Urology Oncology|June 4, 2026
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 StudyPhilipp Cornelius Mandel, Mike Wenzel, María Natalia Gandur Quiroga, et al.
Pageof 8